On the other hand, studies performed in breast cancer cell lines showed that miR-146a acts as a negative regulator of constitutive NF-κB activity by targeting TRAF6 [143], suggesting that miR-146a may act on NF-κB in a negative feedback loop in this cell context. Here, NFKB1 is linked to breast cancer.